Immunocore (NASDAQ:IMCR) Stock Rating Reaffirmed by Cantor Fitzgerald

Immunocore (NASDAQ:IMCR)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a note issued to investors on Monday, Benzinga reports.

A number of other brokerages have also recently commented on IMCR. JPMorgan Chase & Co. cut their price target on shares of Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a research note on Wednesday, July 10th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, August 28th. Barclays dropped their price objective on Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Mizuho reduced their target price on Immunocore from $90.00 to $88.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Finally, Oppenheimer restated an “outperform” rating and issued a $89.00 price target (up previously from $87.00) on shares of Immunocore in a research note on Friday, August 9th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.70.

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $34.26 on Monday. Immunocore has a fifty-two week low of $33.04 and a fifty-two week high of $76.98. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -28.08 and a beta of 0.73. The company has a debt-to-equity ratio of 1.31, a current ratio of 5.17 and a quick ratio of 5.15. The business has a 50-day moving average of $37.51 and a 200-day moving average of $48.16.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. The firm had revenue of $75.40 million during the quarter, compared to the consensus estimate of $74.58 million. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The business’s revenue was up 26.2% compared to the same quarter last year. During the same period last year, the company earned ($0.37) earnings per share. As a group, sell-side analysts predict that Immunocore will post -1.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunocore

A number of hedge funds have recently bought and sold shares of the business. TD Asset Management Inc grew its position in shares of Immunocore by 14.9% during the 4th quarter. TD Asset Management Inc now owns 346,930 shares of the company’s stock worth $23,702,000 after purchasing an additional 45,010 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in Immunocore during the 4th quarter worth $1,314,000. Hsbc Holdings PLC acquired a new position in Immunocore in the 4th quarter valued at $4,450,000. Bellevue Group AG raised its holdings in Immunocore by 4,817.1% in the 4th quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock valued at $66,684,000 after acquiring an additional 956,204 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Immunocore by 1,867.3% during the 2nd quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock valued at $5,435,000 after acquiring an additional 152,207 shares during the period. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.